PLX PROTALIX BIOTHERAPEUTICS INC Investments/Divestments 8-K Filing 2023 - Financial Condition and Other Events Protalix BioTherapeutics, Inc. issued a press release disclosing its cash and cash equivalent position and eligibility for a $20 million milestone payment from Chiesi Global Rare Diseases.Get access to all SEC 8-K filings of the PROTALIX BIOTHERAPEUTICS INC